Skip to main content Skip to main navigation menu Skip to site footer
Published: 23-05-2023

Major considerations of nutrological aspects, gut microbiota, and regulation (down or up-regulation) of microRNAs/exosomes in inflammatory bowel diseases: a systematic review

Santo André II Clinical Center, Santo André, São Paulo, Brazil
HCC Saturnino Lora. Santiago de Cuba, CUBA
HCC Saturnino Lora. Santiago de Cuba, CUBA


Introduction: Inflammatory bowel diseases (IBD) are multifactorial, chronic, continuous, relapsing, and immune-mediated diseases of the gastrointestinal tract. The pathogenesis of IBD is linked to genetically susceptible individuals, dysregulated gut microbiota (dysbiosis), chronic inflammation, and poor dietary patterns. Diet and microRNAs/exosomes play an important role in modulating the intestinal microbiota, and can be applied as a therapeutic tool to improve the course of IBD. Objective: It was to carry out a systematic review of the main considerations of nutrological aspects, intestinal microbiota, and the regulation (Down or Up-regulation) and modulation of microRNAs/exosomes in inflammatory bowel diseases. Methods: The present study followed the international model of systematic review and meta-analysis (PRISMA). Clinical studies were included, involving randomized controlled, prospective, and retrospective studies, as well as pre-clinical studies, published in previous years as gold standard articles until 2023. Results and Conclusion: A total of 154 articles were found. A total of 78 articles were fully evaluated and 55 were included in this systematic review. Considering the Cochrane tool for risk of bias, 22 studies with a high risk of bias and 24 studies that did not meet the GRADE were removed. Most studies showed homogeneity in their results, with X2 =93.5% >50%. The present study analyzed the main interactions between dietary therapy, intestinal microbiota, microRNAs, exosomes, and inflammatory bowel disease, elucidating the main clinical outcomes of the disease after nutrological treatment. As a corollary, important randomized controlled clinical studies were found in the last ten years that showed the important role of diet modulation in the control and even in the remission of inflammatory bowel disease, revealing important reductions in persistent intestinal symptoms, in the balance of the intestinal microbiota, in the regulatory role of microRNAs, reducing inflammation markers and improving quality of life. Recognition of the need for additional data from clinical trials, the inherent uncertainty of efficacy for all inflammatory bowel disease therapies, and the potential for benefit with dietary interventions will help guide progress toward a better understanding of the usefulness of dietary therapy for individuals with inflammatory bowel disease.


Metrics Loading ...


  1. Danilova NA, Abdulkhakov SR, Grigoryeva TV, Markelova MI, Vasilyev IY, Boulygina EA, Ardatskaya MD, Pavlenko AV, Tyakht AV, Odintsova AK, Abdulkhakov RA. Markers of dysbiosis in patients with ulcerative colitis and Crohn's disease. Ter Arkh. 2019 May 15;91(4):17-24. doi: 10.26442/00403660.2019.04.000211.
  2. MINISTÉRIO DA SAÚDE/SECRETARIA DE ATENÇÃO À SAÚDE (PORTARIA CONJUNTA Nº 14, DE 28 DE NOVEMBRO DE 2017). Aprova o Protocolo Clínico e Diretrizes Terapêuticas da Doença de Crohn). Acessado em fevereiro de 2021.
  3. MINISTÉRIO DA SAÚDE/SECRETARIA DE ATENÇÃO À SAÚDE (CONITEC). Protocolo Clínico e Diretrizes Terapêuticas Retocolite Ulcerativa. Acessado em setembro de 2020.
  4. Scaldaferri F, Correale C, Gasbarrini A, Danese S. Mucosal biomarkers in inflammatory bowel disease: Key pathogenic players or disease predictors? World J Gastroenterol. 2010 June 7; 16(21): 2616–2625.
  5. Côté-Daigneault J, Bouin M, Lahaie R, Colombel JF, Poitras P. Biologics in inflammatory bowel disease: what are the data? United European Gastroenterol J. 2015;3(5):419-28.
  6. Roda G, Chien Ng S, Kotze PG, et al. Crohn's disease [published correction appears in Nat Rev Dis Primers. 2020 Apr 6;6(1):26] [published correction appears in Nat Rev Dis Primers. 2020 May 20;6(1):42] [published correction appears in Nat Rev Dis Primers. 2020 Jun 19;6(1):51]. Nat Rev Dis Primers. 2020;6(1):22. Published 2020 Apr 2. doi:10.1038/s41572-020-0156-2
  7. Khanna S, Raffals LE. The Microbiome in Crohn's Disease: Role in Pathogenesis and Role of Microbiome Replacement Therapies. Gastroenterol Clin North Am. 2017 Sep;46(3):481-492. doi: 10.1016/j.gtc.2017.05.004. Epub 2017 Jul 19.
  8. He Q, Gao Y, Jie Z, Yu X, Laursen JM, Xiao L, Li Y, Li L, Zhang F, Feng Q, Li X, Yu J, Liu C, Lan P, Yan T, Liu X, Xu X, Yang H, Wang J, Madsen L, Brix S, Wang J, Kristiansen K, Jia H. Two distinct metacommunities characterize the gut microbiota in Crohn's disease patients. Gigascience. 2017 Jul 1;6(7):1-11. doi: 10.1093/gigascience/gix050.
  9. Green N, Miller T, Suskind D, Lee D. A Review of Dietary Therapy for IBD and a Vision for the Future. Nutrients. 2019 Apr 26;11(5). pii: E947. doi: 10.3390/nu11050947.
  10. Benjamin JL, Hedin CR, Koutsoumpas A, Ng SC, McCarthy NE, Hart AL, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut 2011;60:923-9.
  11. Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B; Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Hospitalisations and surgery in Crohn’s disease. Gut 2012;61:622-9.
  12. Hanauer SB, Sandborn W; Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol 2001;96:635-43.
  13. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 2007;66:30715.
  14. Kirschner BS. Differences in the management of inflammatory bowel disease in children and adolescents compared to adults. Neth J Med 1998;53:S13-8.
  15. Landy J, Al-Hassi HO, McLaughlin SD, et al. Review article: faecal transplantation therapy for gastrointestinal disease. Aliment Pharmacol Ther 2011;34:409-15.
  16. Langholz E, Munkholm P, Krasilnikoff PA, Binder V. Inflammatory bowel diseases with onset in childhood: clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 1997;32:139-47.
  17. Meijer BJ, Dieleman LA. Probiotics in the treatment of human inflammatory bowel diseases: update 2011. J Clin Gastroenterol 2011;45:S139-44.
  18. Shapira SN, Christofk HR. Metabolic Regulation of Tissue Stem Cells. Trends Cell Biol. 2020 Jul;30(7):566-576. doi: 10.1016/j.tcb.2020.04.004.
  19. Basson A. Vitamin D. Crohn’s disease in the adult patient: a review. J Parenter Enteral Nutr. 2014;38:438–58.
  20. Roth MP, Petersen GM, McElree C, Vadheim CM, Panish JF, Rotter JI. Familial empiric risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology. 1989;96(4):1016-20.
  21. Lee YK, Menezes JS, Umesaki Y, Mazmanian SK. Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. 2011;108(suppl 1):4615-4622.
  22. Oliveira ECS, Quaglio AEV, Magro DO, Di Stasi LC, Sassaki LY. Intestinal Microbiota and miRNA in IBD: A Narrative Review about Discoveries and Perspectives for the Future. Int J Mol Sci. 2023 Apr 13;24(8):7176. doi: 10.3390/ijms24087176.
  23. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009) Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097.
  24. Balshem H et al. Grade guidelines: 3 ratng the quality of evidence. Journal of Clinical Epidemiology, Maryland Heights, 2011, v. 64, n. 4, p. 401-406.
  25. Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011.
  26. Bodini G, Zanella C, Crespi M, Lo Pumo S, Demarzo MG, Savarino E, Savarino V, Giannini EG. A randomized, 6-wk trial of a low FODMAP diet in patients with inflammatory bowel disease. Nutrition. 2019 Nov-Dec;67-68:110542. doi: 10.1016/j.nut.2019.06.023. Epub 2019 Jul 1. PMID: 31470260.
  27. Papada E, Amerikanou C, Torović L, Kalogeropoulos N, Tzavara C, Forbes A, Kaliora AC. Plasma free amino acid profile in quiescent Inflammatory Bowel Disease patients orally administered with Mastiha (Pistacia lentiscus); a randomised clinical trial. Phytomedicine. 2019 Mar 15;56:40-47. doi: 10.1016/j.phymed.2018.08.008. Epub 2018 Aug 13. PMID: 30668352.
  28. Jian L, Anqi H, Gang L, Litian W, Yanyan X, Mengdi W, Tong L. Food Exclusion Based on IgG Antibodies Alleviates Symptoms in Ulcerative Colitis: A Prospective Study. Inflamm Bowel Dis. 2018 Aug 16;24(9):1918-1925. doi: 10.1093/ibd/izy110.
  29. Albenberg L, Brensinger CM, Wu Q, Gilroy E, Kappelman MD, Sandler RS, Lewis JD. A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn's Disease Flares. Gastroenterology. 2019 Jul;157(1):128-136.e5. doi: 10.1053/j.gastro.2019.03.015.
  30. Svolos V, Hansen R, Nichols B, Quince C, Ijaz UZ, Papadopoulou RT, Edwards CA, Watson D, Alghamdi A, Brejnrod A, Ansalone C, Duncan H, Gervais L, Tayler R, Salmond J, Bolognini D, Klopfleisch R, Gaya DR, Milling S, Russell RK, Gerasimidis K. Treatment of Active Crohn's Disease With an Ordinary Food-based Diet That Replicates Exclusive Enteral Nutrition. Gastroenterology. 2019 Apr;156(5):1354-1367.e6. doi: 10.1053/j.gastro.2018.12.002.
  31. Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, Cohen S, Peleg S, Shamaly H, On A, Millman P, Abramas L, Ziv-Baran T, Grant S, Abitbol G, Dunn KA, Bielawski JP, Van Limbergen J. Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial. Gastroenterology. 2019 Aug;157(2):440-450.e8. doi: 10.1053/j.gastro.2019.04.021. Epub 2019 Jun 4. PMID: 31170412.
  32. Racine A, Carbonnel F, Chan SS, Hart AR, Bueno-de-Mesquita HB, Oldenburg B, van Schaik FD, Tjønneland A, Olsen A, Dahm CC, Key T, Luben R, Khaw KT, Riboli E, Grip O, Lindgren S, Hallmans G, Karling P, Clavel-Chapelon F, Bergman MM, Boeing H, Kaaks R, Katzke VA, Palli D, Masala G, Jantchou P, Boutron-Ruault MC. Dietary Patterns and Risk of Inflammatory Bowel Disease in Europe: Results from the EPIC Study. Inflamm Bowel Dis. 2016 Feb;22(2):345-54. doi: 10.1097/MIB.0000000000000638. PMID: 26717318.
  33. Braly K, Williamson N, Shaffer ML, Lee D, Wahbeh G, Klein J, Giefer M, Suskind DL. Nutritional Adequacy of the Specific Carbohydrate Diet in Pediatric Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr. 2017 Nov;65(5):533538. doi: 10.1097/MPG.0000000000001613.
  34. Machado JF, Oya V, Coy CS, Morcillo AM, Severino SD, Wu C, Sgarbieri VC, Vilela MM. Whey and soy protein supplements changes body composition in patients with Crohn's disease undergoing azathioprine and anti-TNF-alpha therapy. Nutr Hosp. 2015 Apr 1;31(4):1603-10. doi: 10.3305/nh.2015.31.4.8362. PMID: 25795947.
  35. Brotherton CS, Taylor AG, Bourguignon C, Anderson JG. A high-fiber diet may improve bowel function and health-related quality of life in patients with Crohn disease. Gastroenterol Nurs. 2014 May-Jun;37(3):206-16. doi: 10.1097/SGA.0000000000000047. PMID: 24871666; PMCID: PMC4260718.
  36. Sökülmez P, Demirbağ AE, Arslan P, Dişibeyaz S. Effects of enteral nutritional support on malnourished patients with inflammatory bowel disease by subjective global assessment. Turk J Gastroenterol. 2014 Oct;25(5):493-507. doi: 10.5152/tjg.2014.4955. PMID: 25417609.
  37. Kyaw MH, Moshkovska T, Mayberry J. A prospective, randomized, controlled, exploratory study of comprehensive dietary advice in ulcerative colitis: impact on disease activity and quality of life. Eur J Gastroenterol Hepatol. 2014 Aug;26(8):9107. doi: 10.1097/MEG.0000000000000127. PMID: 24942954.
  38. Hanai H, Iida T, Takeuchi K, Arai H, Arai O, Abe J, Tanaka T, Maruyama Y, Ikeya K, Sugimoto K, Nakamura T, Nakamura K, Watanabe F. Nutritional therapy versus 6-mercaptopurine as maintenance therapy in patients with Crohn's disease. Dig Liver Dis. 2012 Aug;44(8):649-54. doi: 10.1016/j.dld.2012.03.007.
  39. Kang Y, Kim S, Kim SY, Koh H. Effect of short-term partial enteral nutrition on the treatment of younger patients with severe Crohn's disease. Gut Liver. 2015 Jan;9(1):87-93. doi: 10.5009/gnl13345. PMID: 25170058; PMCID: PMC4282862.
  40. Green N, Miller T, Suskind D, Lee D. A Review of Dietary Therapy for IBD and a Vision for the Future. Nutrients. 2019 Apr 26;11(5):947. doi: 10.3390/nu11050947.
  41. Bischoff SC, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, Forbes A, Montoro M, Burgos Peláez R. Guía ESPEN: Nutrición clínica en la enfermedad inflamatoria intestinal [ESPEN guideline: Clinical nutrition in inflammatory bowel disease]. Nutr Hosp. 2022 Jun 24;39(3):678-703. Spanish. doi: 10.20960/nh.03857.
  42. Cusimano FA, Damas OM. Diet as a treatment for inflammatory bowel disease: is it ready for prime time? Curr Opin Gastroenterol. 2022 Jul 1;38(4):358-372. doi: 10.1097/MOG.0000000000000850.
  43. Larabi A, Barnich N, Nguyen HTT. New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD. Autophagy. 2020 Jan;16(1):38-51. doi: 10.1080/15548627.2019.1635384.
  44. Tong L, Hao H, Zhang Z, Lv Y, Liang X, Liu Q, Liu T, Gong P, Zhang L, Cao F, Pastorin G, Lee CN, Chen X, Wang JW, Yi H. Milk-derived extracellular vesicles alleviate ulcerative colitis by regulating the gut immunity and reshaping the gut microbiota. Theranostics. 2021 Jul 25;11(17):8570-8586. doi: 10.7150/thno.62046.
  45. Cui G, Fan Q, Li Z, Goll R, Florholmen J. Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers. EBioMedicine. 2021 Apr;66:103329. doi: 10.1016/j.ebiom.2021.103329.
  46. Iborra M., Moret I., Beltrán B. MicroRNAs as novel biomarkers in IBD: characterization and current status. Biochem Anal Biochem. 2015;4(4).
  47. Batra S.K., Heier C.R., Diaz-Calderon L., Tully C.B., Fiorillo A.A., van den Anker J. Serum miRNAs are pharmacodynamic biomarkers associated with therapeutic response in pediatric inflammatory Bowel disease. Inflamm Bowel Dis. 2020;26(10):1597–1606.
  48. Papaconstantinou I., Kapizioni C., Legaki E., Xourgia E., Karamanolis G., Gklavas A. Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn's disease. World J Gastrointest Pharmacol Ther. 2017;8(4):193–200.
  49. Zhao S, Zhu L, Feng W, Zhang L, Chen DD, Hu YC, Shen H. MicroRNA-602 prevents the development of inflammatory bowel diseases in a microbiota-dependent manner. Exp Ther Med. 2021 Dec;22(6):1373. doi: 10.3892/etm.2021.10808.
  50. Casado-Bedmar M, Viennois E. MicroRNA and Gut Microbiota: Tiny but MightyNovel Insights into Their Cross-talk in Inflammatory Bowel Disease Pathogenesis and Therapeutics. J Crohns Colitis. 2022 Jul 14;16(6):992-1005. doi: 10.1093/eccojcc/jjab223.
  51. Törüner M, Ünal NG. Epigenetics of Inflammatory Bowel Diseases. Turk J Gastroenterol. 2023 May;34(5):437-448. doi: 10.5152/tjg.2023.22515.
  52. Stiegeler S, Mercurio K, Iancu MA, Corr SC. The Impact of MicroRNAs during Inflammatory Bowel Disease: Effects on the Mucus Layer and Intercellular Junctions for Gut Permeability. Cells. 2021 Nov 30;10(12):3358. doi: 10.3390/cells10123358.
  53. Ji Y, Li X, Zhu Y, Li N, Zhang N, Niu M. Faecal microRNA as a biomarker of the activity and prognosis of inflammatory bowel diseases. Biochem Biophys Res Commun. 2018 Sep 18;503(4):2443-2450. doi: 10.1016/j.bbrc.2018.06.174.
  54. Wang H, Ye C, Wu Y, Yang P, Chen C, Liu Z, Wang X. Exosomes in Inflammatory Bowel Disease: What Have We Learned So Far? Curr Drug Targets. 2020;21(14):1448-1455. doi: 10.2174/1389450121666200428102330.
  55. Dhuppar S, Murugaiyan G. miRNA effects on gut homeostasis: therapeutic implications for inflammatory bowel disease. Trends Immunol. 2022 Nov;43(11):917-931. doi: 10.1016/
  56. Chen J, Vitetta L. Is miR-223 Upregulation in Inflammatory Bowel Diseases a Protective Response? Front Biosci (Elite Ed). 2023 Feb 6;15(1):5. doi: 10.31083/j.fbe1501005.
  57. Davoodvandi A, Marzban H, Goleij P, Sahebkar A, Morshedi K, Rezaei S, Mahjoubin-Tehran M, Tarrahimofrad H, Hamblin MR, Mirzaei H. Effects of therapeutic probiotics on modulation of microRNAs. Cell Commun Signal. 2021 Jan 11;19(1):4. doi: 10.1186/s12964-020-00668-w.
  58. Mirzakhani M, Khalili A, Shahbazi M, Abediankenari S, Ebrahimpour S, Mohammadnia-Afrouzi M. Under-expression of microRNA-146a and 21 and their association with Crohn's disease. Indian J Gastroenterol. 2020 Aug;39(4):405-410. doi: 10.1007/s12664-020-01059-2.

How to Cite

Jorrin, M. A., Hernandez Cumbá, S., & Columbié Regüeiferos, J. C. (2023). Major considerations of nutrological aspects, gut microbiota, and regulation (down or up-regulation) of microRNAs/exosomes in inflammatory bowel diseases: a systematic review. International Journal of Nutrology, 16(2).